Sort   by:  
 Page size 
UnknownCombining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
Not available
S-EPMC4164812 | biostudies-literature
UnknownSouthwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Not available
S-EPMC4226807 | biostudies-literature
UnknownPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Not available
S-EPMC4878037 | biostudies-literature
GenomicsCullin-5 RING E3 ligase limits CD8 T-cell persistence and effector responses during chronic antigen stimulation [CRISPR Screen]
Cullin-5 RING E3 ligase limits CD8 T-cell persistence and effector responses during chronic antigen stimulation [CRISPR Screen]
PRJNA1467707 | ENA
GenomicsCullin-5 RING E3 ligase limits CD8 T-cell persistence and effector responses during chronic antigen stimulation [RNA-seq]
Cullin-5 RING E3 ligase limits CD8 T-cell persistence and effector responses during chronic antigen stimulation [RNA-seq]
PRJNA1467717 | ENA
UnknownEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Not available
S-EPMC5070547 | biostudies-literature
UnknownIncidence of cystoid macular edema after Descemet's stripping automated endothelial keratoplasty.
Not available
S-EPMC5514269 | biostudies-literature
UnknownPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Not available
S-EPMC4878048 | biostudies-literature
GenomicHigh Response Rate to Anti PD-1 Therapy in Desmoplastic Melanoma

Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet light DNA damage. We analysed 60 patients with advanced DM treated with programmed cell d...

phs001469 | dbGaP
UnknownProgrammed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Not available
S-EPMC5562434 | biostudies-literature
Sort   by:  
 Page size